时间标签：数据日期 2026-11-05 · 生成时间 2026-11-05 05:30（Asia/Shanghai）｜ 检索窗口 PubMed edat 2026/11/02 – 2026/11/06 ｜ 情报发生日期 2026-11-05
研究问题
The objectives were to describe the populations and comparisons studied, summarize cognitive and biological findings, and identify the measurements and design features needed for clinical translation.；Because the objective was to map evidence types and design implications rather than to estimate a pooled treatment effect, no meta-analysis was undertaken.；Eligible registry records described trials designed to evaluate FMT or whole-microbiota transfer as an investigational intervention for AD, dementia or cognitive impairment, including studies with safety, feasibility, engraftment or mechanistic objectives.
方法
Early access date: October 26, 2026 http://dx.doi.org/10.14336/AD.2026.0883 Review Fecal Microbiota Transplantation in Alzheimer’s Disease: A Scoping Review of Human, Registry, and Preclinical Evidence Jiayi Xu1#, Zhiwen Cao2,3#, Yansong Liu2,3*, Aibo Gao2,3*, Yanyan Kong1* 1 Department of Nuclear Medicine & PET Center, Huashan Hospital, Fudan University, Shanghai, China.；The remaining report was an uncontrolled five-patient pilot comprising two patients with AD, two with mild cognitive impairment (MCI) and one with frontotemporal dementia (FTD).；The published human studies were nonrandomized.
核心结论
Animal FMT studies suggest that microbiota transfer can influence Aβ pathology, neuroinflammation, barrier function and behavioral phenotypes [11, 12].
局限
（原文未给出可直接抽取的对应表述）
对本项目的价值
中高价值：属「微生物组及其代谢物干预」方向；微生物组及其代谢物干预栏目可用作本项目文献库与综述素材。 ｜ 价值分 3.1/5（★★★☆☆）
全文来源
出版商/仓储 OA PDF（正文 21,649 字符，题名指纹 1.0，正文内 DOI 命中，已过题名指纹 + 正文长度归属校验）
原文题录
- 中文题名：粪菌移植治疗阿尔茨海默病：人体、登记与临床前证据的范围综述
- 英文标题：Fecal Microbiota Transplantation in Alzheimer's Disease: A Scoping Review of Human, Registry, and Preclinical Evidence.
- 期刊与标识：Aging and disease · PMID 42970314 · DOI 10.14336/AD.2026.0883